1. Albus M, Naber D, Muller-Spahn E, et al. Tardive dyskinesia: Relation to computer tomographic, endocrine and psychopathological variables. Biol Psychiatry 1985;20:1082-1089.

2. Alvir JMA, J Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.

3. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-1060.

4. Barnes TRE, Liddle PF. Tardive dyskinesia: Implications for schizophrenia? In: Schiff AA, Roth M, Freeman HL, eds. Schizophrenia: New pharmacological and clinical developments. London: Royal Society of Medicine Services, 1985;81-87.

5. Barr WB, Mukherjee M, Caracci G, et al. Neuropsychological studies in tardive dyskinesia: A possible relationship with anomalous dominance. Society of Biological Psychiatry, 42nd Annual Convention and Scientific Program, 295, 1987.

6. Bogerts B, Ashtari M, Degreef G, et al. Reduced temporal-limbic structure volumes on magnetic resonance images in first-episode schizophrenia. Psychiatr Res 1990;35:1-13.

7. Buckley P, Callaghan E, Mulvany F, et al. Basal ganglia T2 relaxation times in schizophrenia: A quantitative magnetic resonance imaging study in relation to tardive dyskinesia. Psychiatry Res 1995;61:95-102.

8. Burke RE, Kang UJ. Tardive dystonia: Clinical aspects and treatment. In: Jankovic J, Tolosa E, eds. Facial Dyskinesias. New York: Raven Press, 1988;199-210.

9. Campbell M, Grega DM, Green WH, et al. Review: Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 1983;6:207-222.

10. Casey DE, Gardos G. Tardive dyskinesia: Outcome at 10 years. Schizophr Res 1990;3:11.

11. Casey DE, Gerlach J. Tardive dyskinesia: What is the long-term outcome. In: Casey DE, Gardos G, eds. Tardive dyskinesia and neuroleptics: From dogma to reason. Washington, D.C.: American Psychiatric Press, 1986;75-97.

12. Casey DE. Affective disorders and tardive dyskinesia. Encephale 1988;14:221-226.

13. Casey DE. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99:S47-S53.

14. Chakos MH, Alvir JMJ, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first-episode of schizophrenia. Arch Gen Psychiatry 1996;53:313-319.

15. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729.

16. Chorfi M, Moussaoui D. Lack of dyskinesias in unmedicated schizophrenics. Psychopharmacology 1989;97:423.

17. Chouinard G, Annable L, Ross-Chouinard A, Holobow N. Factors affecting the course of tardive dyskinesia: A ten-year follow-up. Presented at the American Psychiatric Association Meeting, New York, May 12-17, 1990.

18. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comp Psychiatry 1992;33:121-122.

19. Duke PJ, Pantelis C, Barnes TRE. Alcohol use in schizophrenia: Symptomatology, relationship with tardive dyskinesia, akathisia and age of onset. Br J Psychiatry 1994;164:630-634.

20. Fairbairn AF, Rowell FJ, Hui SM, et al. Serum concentration of depot neuroleptics in tardive dyskinesia. Br J Psychiatry 1983;142:579-583.

21. Farran-Ridge C. Some syndromes referable to the basal ganglia occurring in dementia praecox and epidemic encephalitis. J Mental Sci 1926;72:513-523.

22. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994;51:643-650.

23. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. Arch Gen Psychiatry 1991;48:259-263.

24. Gardos G, Casey DE, Cole JO, et al. Ten year outcome of tardive dyskinesia. Am J Psychiatry 1994;151:836-841.

25. Gardos G, Cole JO, La Brie RA. Drug variables in the etiology of tardive dyskinesia: Application of discriminant function analysis. Prog Neuropsychopharmacol 1977;1:147-154.

26. Gardos G, Cole JO, Haskell D, et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol 1988;8(suppl 4):31-33.

27. Gardos G, Cole JO. Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 1993;140:200-202.

28. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157:585-592.

29. Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia: A retrospective follow-up study. Br J Psychiatry 1991;158:822-828.

30. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993;54:133-139.

31. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry 1981;138:297-309.

32. Jeste DV, DeLisi LE, Zaleman S, et al. A biochemical study of tardive dyskinesia in young male patients. Psychiatry Res 1981;4:327-331.

33. Jeste DV, Linnoila M, Wagner RL, et al. Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacology 1982;76:377-386.

34. Jeste DV, Karson CM, Iager AC, et al. Association of abnormal involuntary movements and negative symptoms. Psychopharmacol Bull 1984;20:380-381.

35. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.

36. Kane JM, Smith JM. Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry 1982;39:473-481.

37. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 1983;40:893-896.

38. Kane J, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254-258.

39. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: Prevalence, incidence and risk factors. J Clin Psychopharmacol 1988;8:52S-56S.

40. Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 1992.

41. Kane JM, Marder SR. Pharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302.

42. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1:193-208.

43. Kaufmann CA, Jeste DV, Shelton RC, et al. Noradrenergic and neuroradiologic abnormalities in tardive dyskinesia. Biol Psychiatry 1986;21:799-812.

44. Kraepelin EP. Dementia praecox and paraphrenia. Translated by Barclay RM. Edited by Robertson GM. Edinburgh, E & S Livingstone, 1919.

45. Levine J, Schooler N, Severe J, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: A controlled study. Psychopharmacology 1980;24:483-493.

46. Lidsky TI, Weinhold PM, Levine FM; Implications of basal ganglionic dysfunction for schizophrenia. Biol Psychiatry 1979;14:3-12.

47. Manschrek TC, Maher BA, Rucklos ME, et al. Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med 1982;12:73-84.

48. Mettler FA, Crandell A. Neurologic disorders in psychiatric institutions. J Nerv Ment Dis 1959;128:148-159.

49. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: Results of the Yale TD study. Arch Gen Psychiatry 1993;50:723-733.

50. Mukherjee S, Sackeim HA, Schnur DB. Tardive dyskinesia and family history of diabetes mellitus. Arch Gen Psychiatry, in press, 1997.

51. Mukherjee S, Wisniewsky A, Bilder RM, Sackeim HA. Possible association between tardive dyskinesia and altered carbohydrate metabolism. Arch Gen Psychiatry 1985;42:205.

52. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia and psychiatric patients with substance abuse disorders. Am J Drug Alcohol Abuse 1990;16:57-66.

53. Owens DGC, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: Their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982;39:452-461.

54. Paulsen JS, Caligiuri MP, Palmer B, et al. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study. Psychopharmacology 1996;123:307-314.

55. Pert A, Rosenblatt JE, Sivit C, et al. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978;201:171-173.

56. Richardson MA, Pass R, Bregman Z, et al. Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacol Bull 1985;21:130-135.

57. Rosenbaum AH, Niven RG, Hanson HP, et al. Tardive dyskinesia: Relationship with primary affective disorder. Dis Nerv Sys 1977;38:423-427.

58. Rush M, Diamond F, Alpert M. Depression as a risk factor in tardive dyskinesia. Biol Psychiatry 1982;17:387-392.

59. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406.

60. Segal DS, Janowsky DS. Psychostimulant-induced behavioral effects: Possible models of schizophrenia. In: Lipton MA, DiMascio AD, Killam KF, eds. Psychopharmacology: A generation of progress. New York: Raven Press, 1978;1113-1123.

61. Smith RC, Strizich M, Klass D. Drug history and tardive dyskinesia. Am J Psychiatry 1978;135:1402-1403.

62. Soni SD, Neill D. Tardive dyskinesia and cognitive functions in schizophrenia. Schizophr Res 1990;3:78.

63. Sorokin JE, Giordani B, Mohs RC, et al. Memory impairment in schizophrenic patients with tardive dyskinesia. Biol Psychiatry 1988;23:129-135.

64. Suddath RI, Christison GW, Torrey EF, Weinberger DR. Cerebral anatomical abnormalities in monozygotic twins discordant for schizophrenia. N Engl J Med 1990;322:789-794.

65. Waddington JL. Tardive dyskinesia in schizophrenia and other disorders: Association with aging, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharmacol 1987;2:11-22.

66. Waddington JL, Youssef HA, Dolphin C, et al. Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia: Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 1987;44:907-912.

67. Waddington JL, Brown K, O'Neill J. Cognitive impairment, clinical course and treatment history in outpatients with bipolar affective disorder: Relationship to tardive dyskinesia. Psychol Med 1989;19:897-902.

68. Waddington JL. Schizophrenia, affective psychoses and other disorders treated with neuroleptic drugs: The enigma of tardive dyskinesia, its neurobiological determinants and the conflict of paradigms. Int Rev Neurobiol 1989;31:297-353.

69. Waddington JL. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 1990;101:431-447.

70. Waddington JL. Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Adv Neurol 1995;65:211-229.

71. Wegner JT, Catalano F, Gibralter J, et al. Schizophrenics with tardive dyskinesia: Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry 1985;42:860-865.

72. Woerner M, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.

73. Woerner M, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993;150:966-968.

74. Yagi G, Itoh H. Follow-up study of 11 patients with potentially reversible tardive dyskinesia. Am J Psychiatry 1987;144:1496-1498.

75. Yarden PE, Discipio WJ. Abnormal movements and prognosis in schizophrenia. Am J Psychiatry 1971;128:317-323.

76. Yassa R, Nair V, Schwartz G. Tardive dyskinesia: A two-year follow-up study. Psychosomatics 1984;25:852-855.

77. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984;25:135-138.

78. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.

79. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull 1992;18:701-715.

80. Yesavage JA, Tauke ED, Sheikh. Tardive dyskinesia and steady-state serum levels of thiothixene. Arch Gen Psychiatry 1987;44:913-915.

Back to Chapter